NO20021475L - Vasopressin antagonist, formulation and method - Google Patents
Vasopressin antagonist, formulation and methodInfo
- Publication number
- NO20021475L NO20021475L NO20021475A NO20021475A NO20021475L NO 20021475 L NO20021475 L NO 20021475L NO 20021475 A NO20021475 A NO 20021475A NO 20021475 A NO20021475 A NO 20021475A NO 20021475 L NO20021475 L NO 20021475L
- Authority
- NO
- Norway
- Prior art keywords
- component
- formulation
- pharmaceutically acceptable
- vasopressin antagonist
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Abstract
Det er beskrevet nye formuleringer for N-[4-(5H-pyrrolo[2,1-c][1,4]benzo- diazepin-10(11H)ylkarbonyl)-3-klorfenyl]-5-fluor-2-metyl-benzamid eller et farmasøytisk akseptabelt salt derav, og fremgangsmåter for fremstilling av disse, idet formuleringene omfatter fra omtrent 1 % til omtrent 20 % aktiv ingrediens, fra omtrent 1 % til omtrent 18 % av en overflateaktiv middel- komponenet, fra omtrent 50 % til omtrent 80 % av en komponent av en eller flere polyetylenglykoler, fra omtrent 1 % til omtrent 20 % av en komponent av en eller flere sukrosefettsyrer og/eller polyvinylpyrrolidon, og eventuelt en eller flere farmasøytisk akseptable konserveringsmidler eller antioksydanter.New formulations for N- [4- (5H-pyrrolo [2,1-c] [1,4] benzodiazepin-10 (11H) ylcarbonyl) -3-chlorophenyl] -5-fluoro-2-methyl are described. benzamide or a pharmaceutically acceptable salt thereof, and processes for their preparation, the formulations comprising from about 1% to about 20% of active ingredient, from about 1% to about 18% of a surfactant component, from about 50% to about 80% of a component of one or more polyethylene glycols, from about 1% to about 20% of a component of one or more sucrose fatty acids and / or polyvinylpyrrolidone, and optionally one or more pharmaceutically acceptable preservatives or antioxidants.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40577299A | 1999-09-27 | 1999-09-27 | |
PCT/US2000/026369 WO2001022945A1 (en) | 1999-09-27 | 2000-09-26 | Vasopressin antagonist formulation and process |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20021475D0 NO20021475D0 (en) | 2002-03-25 |
NO20021475L true NO20021475L (en) | 2002-04-16 |
Family
ID=23605168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20021475A NO20021475L (en) | 1999-09-27 | 2002-03-25 | Vasopressin antagonist, formulation and method |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1216033A1 (en) |
JP (1) | JP2003510269A (en) |
KR (1) | KR20020039354A (en) |
CN (1) | CN1391466A (en) |
AR (1) | AR025780A1 (en) |
AU (1) | AU7615000A (en) |
BR (1) | BR0014351A (en) |
CA (1) | CA2388474A1 (en) |
CZ (1) | CZ20021083A3 (en) |
EA (1) | EA200200414A1 (en) |
HK (1) | HK1045109A1 (en) |
HU (1) | HUP0202972A3 (en) |
IL (1) | IL148541A0 (en) |
MX (1) | MXPA02003189A (en) |
NO (1) | NO20021475L (en) |
PL (1) | PL354282A1 (en) |
WO (1) | WO2001022945A1 (en) |
ZA (1) | ZA200203312B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030105144A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
JP4632288B2 (en) * | 2002-02-27 | 2011-02-16 | 塩野義製薬株式会社 | Solid formulation with improved absorption of poorly water-soluble drugs |
JP5873375B2 (en) * | 2012-04-03 | 2016-03-01 | 中日本カプセル 株式会社 | Soft capsule and method for producing soft capsule |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5516774A (en) * | 1993-07-29 | 1996-05-14 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
US6287594B1 (en) * | 1998-01-20 | 2001-09-11 | Edward S. Wilson | Oral liquid compositions |
-
2000
- 2000-09-26 MX MXPA02003189A patent/MXPA02003189A/en not_active Application Discontinuation
- 2000-09-26 BR BR0014351-0A patent/BR0014351A/en not_active Application Discontinuation
- 2000-09-26 IL IL14854100A patent/IL148541A0/en unknown
- 2000-09-26 CA CA002388474A patent/CA2388474A1/en not_active Abandoned
- 2000-09-26 AU AU76150/00A patent/AU7615000A/en not_active Abandoned
- 2000-09-26 PL PL00354282A patent/PL354282A1/en not_active Application Discontinuation
- 2000-09-26 HU HU0202972A patent/HUP0202972A3/en unknown
- 2000-09-26 CZ CZ20021083A patent/CZ20021083A3/en unknown
- 2000-09-26 EP EP00965430A patent/EP1216033A1/en not_active Withdrawn
- 2000-09-26 JP JP2001526157A patent/JP2003510269A/en active Pending
- 2000-09-26 CN CN00816008A patent/CN1391466A/en active Pending
- 2000-09-26 WO PCT/US2000/026369 patent/WO2001022945A1/en not_active Application Discontinuation
- 2000-09-26 EA EA200200414A patent/EA200200414A1/en unknown
- 2000-09-26 KR KR1020027003931A patent/KR20020039354A/en not_active Application Discontinuation
- 2000-09-26 AR ARP000105036A patent/AR025780A1/en unknown
-
2002
- 2002-03-25 NO NO20021475A patent/NO20021475L/en not_active Application Discontinuation
- 2002-04-25 ZA ZA200203312A patent/ZA200203312B/en unknown
- 2002-09-05 HK HK02106544.6A patent/HK1045109A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CZ20021083A3 (en) | 2002-06-12 |
CA2388474A1 (en) | 2001-04-05 |
CN1391466A (en) | 2003-01-15 |
HUP0202972A2 (en) | 2002-12-28 |
EA200200414A1 (en) | 2002-12-26 |
JP2003510269A (en) | 2003-03-18 |
WO2001022945A1 (en) | 2001-04-05 |
BR0014351A (en) | 2002-06-11 |
PL354282A1 (en) | 2003-12-29 |
MXPA02003189A (en) | 2002-09-30 |
NO20021475D0 (en) | 2002-03-25 |
ZA200203312B (en) | 2003-12-31 |
IL148541A0 (en) | 2002-09-12 |
EP1216033A1 (en) | 2002-06-26 |
AU7615000A (en) | 2001-04-30 |
AR025780A1 (en) | 2002-12-11 |
KR20020039354A (en) | 2002-05-25 |
HUP0202972A3 (en) | 2003-07-28 |
HK1045109A1 (en) | 2002-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2271196A1 (en) | Pharmaceutical compositions of hiv protease inhibitors with improved oral bioavailability | |
NZ511903A (en) | Use of alpha-keto enamine derivatives as ingredients | |
NZ506989A (en) | Fizzy formulations for an alkali sensitive active agents containing organic edible acid and an alkaline earth carbonate | |
DE69711637D1 (en) | AEROSOL FORMULATIONS | |
YU39800A (en) | Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors | |
RS50360B (en) | Platinum derivative pharmaceutical formulations | |
HUP0004383A2 (en) | Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient | |
MXPA05002871A (en) | Benzodiazepine derivatives and pharmaceutical compositions containing them. | |
RS52548B (en) | Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient | |
MY127749A (en) | Liquid formulation | |
CA2360300A1 (en) | A transdermal composition of an antivomiting agent and a preparation containing the same | |
NO20021475L (en) | Vasopressin antagonist, formulation and method | |
ATE253359T1 (en) | ANTITHRBOTIC AGENTS | |
WO2001022969A3 (en) | Vasopressin agonist formulation and process | |
DE69828522D1 (en) | ANTITROMOMBOTIC AGENTS | |
NO20021476L (en) | Pharmaceutical borer formulation | |
DE69927997D1 (en) | Novel pyrimidine derivatives and method for their preparation | |
EP0056681A3 (en) | Levonantradol and n-methyllevonantradol formulations | |
NZ521515A (en) | Composition comprising paracetamol and niflumic acid | |
DE69824410D1 (en) | Antithrombosemittel | |
UY28095A1 (en) | PHARMACEUTICAL COMPOSITION | |
AU1434201A (en) | Antithrombotic agents | |
MY116032A (en) | Liquid composition comprising an hiv protease inhibitor and a, c12-c18 fatty acid | |
MX9702532A (en) | Pharmaceutical compositions for the treatment of rhinitis. | |
JO1664B1 (en) | Compomnd with gastric acid inhibitory effect and process for its preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |